Novartis AG (NVS)
Pre-market:
| Previous close | 115.72 |
| Open | 115.81 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1800 |
| Day's range | 115.28 - 116.32 |
| 52-week range | 92.19 - 120.92 |
| Volume | |
| Avg. volume | 1,247,382 |
| Market cap | 234.163B |
| Beta (5Y monthly) | 0.50 |
| PE ratio (TTM) | 23.65 |
| EPS (TTM) | 4.89 |
| Earnings date | 29 Oct 2024 |
| Forward dividend & yield | 3.78 (3.27%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | 117.31 |
GlobeNewswireNovartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease1Results remain consistent across secondary endpoints, including distant disease-free survival, with a trend for improved overall survival*1Safety is in line with previously reported results with generally low-grade symptomatic adverse events, reinforcing well-tolerated profile1People diagnosed with stage II or II
ZacksBoost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
ZacksWhy This 1 Value Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
